Invivyd (NASDAQ:IVVD – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03, FiscalAI reports. The company had revenue of $15.45 million during the quarter, compared to analyst estimates of $15.04 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%.
Invivyd Stock Performance
NASDAQ:IVVD opened at $0.58 on Monday. The company’s 50 day moving average is $0.72 and its two-hundred day moving average is $1.09. Invivyd has a twelve month low of $0.53 and a twelve month high of $3.07. The company has a market cap of $171.58 million, a PE ratio of -1.76 and a beta of 1.20.
Wall Street Analyst Weigh In
A number of brokerages have commented on IVVD. Weiss Ratings upgraded shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 8th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday, September 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Invivyd in a report on Thursday, August 27th. Finally, BTIG Research reissued a “buy” rating on shares of Invivyd in a research note on Monday, September 14th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Invivyd presently has an average rating of “Hold” and a consensus target price of $10.00.
Insider Activity
In other news, insider Jill Andersen sold 30,706 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total value of $25,793.04. Following the completion of the transaction, the insider owned 283,774 shares of the company’s stock, valued at $238,370.16. The trade was a 9.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 103,024 shares of company stock worth $86,540 over the last three months. Company insiders own 12.25% of the company’s stock.
Invivyd Company Profile
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
Read More
- Five stocks we like better than Invivyd
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
